Welcome to Pharmaxis

Pharmaxis is a research-based specialist pharmaceutical company with a portfolio of products at various stages of development and approval.  

Company Highlights

Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate

Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired  the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.

Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor for Pulmonary Fibrosis

Pharmaxis Ltd and UK biotechnology company Synairgen plc (LSE: SNG) today announced they have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

Pharmaxis signs second agreement with Chiesi

Pharmaxis has entered into an exclusive distribution and supply agreement with global pharmaceutical company Chiesi Farmaceutici SpA (Chiesi) for the commercialisation of Bronchitol® (mannitol) for cystic fibrosis in adults aged 18 years and above in Germany, the United Kingdom and Ireland.


Pharmaxis in the news.

Executive Snapshot by Acquisdata

Interview with Gary Phillips, CEO Pharmaxis Ltd - 23 October 2015

Click here for interviews